文献速递冠心病

替格瑞洛单药治疗在ACS行PCI患者中的安全性和有效性:TWILIGHT与TICO随机试验个体患者数据荟萃分析

Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.
PubMed 文献 · Circulation · 2023-10-23

该研究汇总TWILIGHT和TICO两项随机试验的个体患者数据,纳入接受PCI且完成3个月双联抗血小板治疗后无事件的ACS患者7529例,比较替格瑞洛单药与替格瑞洛联合阿司匹林。结果显示替格瑞洛单药显著降低3至12个月BARC 3或5型出血(0.8% vs 2.1%;HR 0.37;95%CI 0.24-0.56;P<0.001),且死亡、心肌梗死或卒中复合终点无显著差异(2.4% vs 2.7%;HR 0.91;95%CI 0.68-1.21;P=0.515)。

要点

  • ACS行PCI患者完成3个月DAPT后,替格瑞洛单药较继续联合阿司匹林显著降低大出血风险。
  • 替格瑞洛单药不增加死亡、心肌梗死或卒中复合缺血事件风险。
  • 生物标志物阳性ACS亚组中,替格瑞洛单药的获益与总体人群一致。

核心结论

  • ACS行PCI患者完成3个月双联抗血小板治疗后,停用阿司匹林改为替格瑞洛单药可显著降低大出血且不增加缺血风险。

研究设计与样本

  • 汇总TWILIGHT和TICO随机试验的个体患者数据,纳入ACS行PCI且初始3个月双联抗血小板治疗后无主要缺血或出血事件的患者7529例。
  • 比较替格瑞洛单药与继续替格瑞洛联合阿司匹林,采用Cox回归一阶段法在意向治疗人群分析。

主要发现

  • 3至12个月BARC 3或5型出血替格瑞洛单药组0.8%,替格瑞洛联合阿司匹林组2.1%(HR 0.37;95%CI 0.24-0.56;P<0.001)。
  • 死亡、心肌梗死或卒中复合终点两组分别为2.4%和2.7%(HR 0.91;95%CI 0.68-1.21;P=0.515)。
  • 生物标志物阳性ACS患者中结果与总体人群一致。

关键数值与推荐

  • 主要终点为PCI后3至12个月BARC 3或5型出血。
  • 关键次要终点为死亡、心肌梗死或卒中复合终点。
  • 纳入人群平均年龄62.8岁,女性占23.2%,生物标志物阳性ACS占55%。

临床怎么用

  • 对于ACS行PCI且已完成3个月双联抗血小板治疗无事件的患者,可考虑停用阿司匹林,改用替格瑞洛单药以降低出血风险。

局限性

  • 分析排除了PCI后3个月内发生主要缺血或出血事件的患者。
  • 仅纳入TWILIGHT和TICO两项试验的个体数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual antiplatelet therapy with a potent P2Y12 inhibitor coupled with aspirin for 1 year is the recommended treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). As an alternative, monotherapy with a P2Y12 inhibitor after a short period of dual antiplatelet therapy has emerged as a bleeding reduction strategy. METHODS: We pooled individual patient data from randomized trials that included patients with ACS undergoing PCI treated with an initial 3-month course of dual antiplatelet therapy followed by ticagrelor monotherapy versus continued ticagrelor plus aspirin. Patients sustaining a major ischemic or bleeding event in the first 3 months after PCI were excluded from analysis. The primary outcome was Bleeding Academic Research Consortium type 3 or 5 bleeding occurring between 3 and 12 months after index PCI. The key secondary end point was the composite of death, myocardial infarction, or stroke. Hazard ratios and 95% CIs were generated using Cox regression with a one-stage approach in the intention-to-treat population. RESULTS: The pooled cohort (n=7529) had a mean age of 62.8 years, 23.2% were female, and 55% presented with biomarker-positive ACS. Between 3 and 12 months, ticagrelor monotherapy significantly reduced Bleeding Academic Research Consortium 3 or 5 bleeding compared with ticagrelor plus aspirin (0.8% versus 2.1%; hazard ratio, 0.37 [95% CI, 0.24-0.56]; P<0.001). Rates of all-cause death, myocardial infarction, or stroke were not significantly different between groups (2.4% versus 2.7%; hazard ratio, 0.91 [95% CI, 0.68-1.21]; P=0.515). Findings were unchanged among patients presenting with biomarker-positive ACS. CONCLUSIONS: Among patients with ACS undergoing PCI who have completed a 3-month course of dual antiplatelet therapy, discontinuation of aspirin followed by ticagrelor monotherapy significantly reduced major bleeding without incremental ischemic risk compared with ticagrelor plus aspirin. REGISTRATION: URL: https://www.crd.york.ac.uk/prospero; Unique identifier: CRD42023449646.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Baber, Jang, Oliva, et al. Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials. Circulation. 2023. PMID: 37870970. doi:10.1161/CIRCULATIONAHA.123.067283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。